Eton Pharmaceuticals, Inc. ETON Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eton Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eton Pharmaceuticals, Inc.'s retained earnings?
- Eton Pharmaceuticals, Inc. (ETON) reported retained earnings of -$110.94M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Eton Pharmaceuticals, Inc.'s retained earnings decreased by 1.3% year-over-year, from -$109.47M to -$110.94M.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s retained earnings has grown at a 4.1% compound annual growth rate (CAGR), from -$92.16M to -$112.49M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.